Market closed
DiaMedica Therapeutics Inc. Common Stock/$DMAC
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About DiaMedica Therapeutics Inc. Common Stock
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
Ticker
$DMAC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
19
Website
DMAC Metrics
BasicAdvanced
$208M
Market cap
-
P/E ratio
-$0.55
EPS
1.46
Beta
-
Dividend rate
Price and volume
Market cap
$208M
Beta
1.46
52-week high
$5.43
52-week low
$2.14
Average daily volume
125K
Financial strength
Current ratio
11.815
Quick ratio
11.749
Long term debt to equity
0.548
Total debt to equity
0.761
Management effectiveness
Return on assets (TTM)
-27.23%
Return on equity (TTM)
-41.90%
Valuation
Price to book
4.34
Price to tangible book (TTM)
4.34
Price to free cash flow (TTM)
-9.804
Growth
Earnings per share change (TTM)
-8.59%
3-year earnings per share growth (CAGR)
-10.50%
What the Analysts think about DMAC
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for DiaMedica Therapeutics Inc. Common Stock stock.
DMAC Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DMAC Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DMAC News
AllArticlesVideos
DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript
Seeking Alpha·1 month ago
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2024 Financial Results
Business Wire·1 month ago
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for DiaMedica Therapeutics Inc. Common Stock stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a market cap of $208M as of December 21, 2024.
What is the P/E ratio for DiaMedica Therapeutics Inc. Common Stock stock?
The price to earnings (P/E) ratio for DiaMedica Therapeutics Inc. Common Stock (DMAC) stock is 0 as of December 21, 2024.
Does DiaMedica Therapeutics Inc. Common Stock stock pay dividends?
No, DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders as of December 21, 2024.
When is the next DiaMedica Therapeutics Inc. Common Stock dividend payment date?
DiaMedica Therapeutics Inc. Common Stock (DMAC) stock does not pay dividends to its shareholders.
What is the beta indicator for DiaMedica Therapeutics Inc. Common Stock?
DiaMedica Therapeutics Inc. Common Stock (DMAC) has a beta rating of 1.46. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.